Effects of recombinant human growth hormone on intestinal translocation of bacteria and endotoxin in rats with obstructive jaundice

Extrahepatic biliary obstruction promotes intestinal translocation of bacteria and endotoxin and this process is an important cause of morbidity and mortality in patients with jaundice. This study was undertaken to investigate the effect and mechanism of recombinant human growth hormone (rhGH) and to alleviate intestinal translocation of bacteria and endotoxin in murine obstructive jaundice. METHODS:A group of 42 Wistar rats were divided into 3 groups:sham operation (SO), bile duct ligation (BDL), and BDL and rhGH treatment (rhGH). By the end of the experiment,on day 7, the animals were killed, and their liver function and serum endotoxin were measured, bacterial cultures of the liver, kidney and mesenchymal lymph were made. Terminal ileum mucosa was observed under an electron microscope. RESULTS:Liver function was improved more significantly in the rhGH group than in the BDL group. The value of endotoxin in the rhGH group was 0.38±0.03 EU/ml, significantly lower than that in the BDL group (0.65±0.04 EU/ml, P【0.01), and similar to that in the SO group (0.30±0.02 EU/ml, P】0.05). The rate of bacteria translocation in the liver, kidney and mesenteric lymph was much higher in the BDL group than in other two groups. The rate of bacteria translocation in mesenteric lymph was 64.29%,significantly higher than that in the SO group and the rhGH group (P【0.05). There was no significant difference in bacteria translocation rate between the SO group and the rhGH group (P】0.05). Under an electron microscope , ileum mucosa epithelial cells in the BDL group were necrotic, and organelle were markedly metamorphic. In the rhGH group, ultrastructural changes were less evident or similar to those in the SO group. CONCLUSION:rhGH has significant protective effects on intestinal mucosa barrier in obstructive jaundice, and reduces intestinal translocation of bacteria and endotoxin.

Altered Nutrition State in the Severe Multiple Trauma Patients Undergoing Adjuvant Recombinant Human Growth Hormone Nutritional Support Therapy

In order to observe the nutrition state in the severe multiple trauma patients undergoing adjuvant recombinant human growth hormone (rhGH) nutritional support therapy, 45 patients with severe multiple traumas (ISS>25) were randomly divided into 3 groups. All the 3 groups had been supplied with nitrogen and caloricity according to the need of patients for 16 days. The rhGH therapy started 48 h after surgery and lasted for 14 days in two rhGH-treated groups in which rhGH was 0.2 and 0.4 U/(kg·d) respectively, and the resting group served as control one. The levels of nitrogen balance, prealbumin and safety variables (blood sugar, Na+, TT3 and TT4) were observed and com- pared among the three groups. The levels of nitrogen balance on the postoperative day (POD) 3 and 5 in the rhGH-treated groups were -1.28±3.19, 5.45±2.00 and -0.18±2.55, 6.11±1.60, respectively, which were significantly higher than those in the control group (-5.17±1.68 and -1.08±3.31, P<0.01). The values of prealbumin on the POD 3 and 5 in the rhGH-treated groups were 180.19±27.15, 194.44±50.82 and 194.94±29.65, 194.11±16.17, respectively, which were significantly higher than those in the control group (117.42±19.10 and 135.63±28.31, P<0.01). There was no sig- nificant difference between the rhGH 0.2 U/(kg·d) group and rhGH 0.4 U/(kg·d) group in both of the levels of nitrogen balance and prealbumin. It is concluded that the nutritional support therapy with adjuvant rhGH which starts 48 h after surgery improves the nutrition state of the patients with severe multiple trauma. It is safe for severe multiple trauma patients who accept rhGH at the dose of 0.2 and 0.4 U/(kg·d).

Effects of recombinant human growth hormone on enterocutaneous fistula patients

AIM： To explore the effects of recombinant human growth hormone （rhGH） on intestinal mucosal epithelial cell proliferation and nutritional status in patients with enterocutaneous fistula. METHODS： Eight patients with enterocutaneous fistulas received recombinant human growth hormone （10 ug/d） for 7 d. Image analysis and immunohistochemical techniques were used to analyse the expression of proliferating cell nuclear antigen （PCNA） in intestinal mucosal epithelial cells in biopsy samples from the patients who had undergone an endoscopic biopsy through the fistula at day 0, 4 and 7. Body weights, nitrogen excretion, serum levels of total proteins, albumin, prealbumin, transferrin and fibronectin were measured at day 0, 4 and 7. RESULTS： Significant improvements occurred in the expression of PCNA in the intestinal mucosal epithelial cells at day 4 and 7 compared to day 0 （24.93 ± 3.41%, 30.46 ± 5.24% vs 12.92 ± 4.20%, p 〈 0.01）. These changes were accompanied by the significant improvement of villus height （500.54 ± 53.79 um, 459.03 ± 88.98um vs 210.94 ± 49.16 um, P 〈 0.01）, serum levels of total proteins （70.52 ± 5.13 g/L, 74.89 ± 5.16 g/L vs 63.51 ± 2.47 g/L, P 〈 0.01）, albumin （39.44 ± 1.18 g/L, 42.39 ± 1.68 g/L vs 35.74 ± 1.75 g/L, P 〈 0.01） and fibronectin （236.3 4- 16.5 mg/L, 275.8± 16.9 mg/L vs 172.5 ± 21.4 mg/L, P 〈 0.01） at day 4 and 7, and prealbumin （286.38 ± 65.61 mg/L vs 180.88 ± 48.28 mg/L, P 〈 0.05）, transferrin （2.61 ± 0.12 g/L vs 2.41 ±0.14 g/L, P 〈 0.05） at day 7. Nitrogen excretion was significantly decreased at day 7 （3.40 ± 1.65 g/d vs 7.25 ± 3.92 g/d, P 〈 0.05）. No change was observed in the body weight. CONCLUSION： Recombinant human growth hormone could promote intestinal mucosal epithelial cell proliferation and protein synthesis in patients with enterocutaneous fistula.

Experimental study on effect of recombinant human growth hormone combined with chemotherapy on stomach neoplasms implanted in nude mice

Objective: To investigate the effect of different doses of recombined growth hormone (rhGH) on stomach neo- plasms implanted in nude mice, and its efficacy in combining with chemotherapy (flurouracil, 5-FU). Methods: Human stom- ach neoplasms model was established in nude mice. The nude mice were divided into control group, moderate-dose of rhGH group, low-dose rhGH group, 5-FU group, moderate-dose rhGH/5-FU group, and low-dose rhGH/5-FU group. The results of each group were observed after ten days. Results: After therapy, the body mass of rhGH groups was significantly increased compared with control group (P<0.05), the body mass of rhGH/5-FU groups was significantly increased compared with 5-FU group (P<0.05), but it was no significant difference between rhGH/5-FU groups and control group (P>0.05). The average tumor mass and volume of rhGH groups were not significantly increased compared with control group (P>0.05), but they were significantly reduced in 5-FU group and rhGH/5-FU groups (P<0.05). They were no significant difference between rhGH/5- FU groups and 5-FU group (P>0.05). After treatment, the percentages of S, G0/G1 and G2/M phases and proliferation index (PI) were not significantly changed in rhGH groups compared with control group (P>0.05), and the same with rhGH/5-FU groups compared with 5-FU group (P>0.05). The difference caused by dose of rhGH was not significant. Conclusion: rhGH enhances body mass, does not stimulate tumor growth, and has no adverse effects on tumor bearing nude mice. Combined with flurouracil, rhGH does not influence the efficacy of chemotherapy, and has no effect on tumor cell cycle kinetics.

Protective effect of perioperative recombinant human growth hormone application on intestinal mucosal barrier function in patients with intestinal obstruction and the assessment of immune inflammatory response

Objective:To study the protective effect of perioperative recombinant human growth hormone (r-hGH) application on intestinal mucosal barrier function in patients with intestinal obstruction and the influence on the immune inflammatory response.Methods:60 patients with intestinal obstruction who underwent surgical treatment in our hospital between February 2013 and July 2016 were selected as the research subjects and divided into the control group (n=34) who received conventional surgical treatment and the observation group (n=26) who received surgery combined with perioperative r-hGH treatment. The serum levels of intestinal mucosal barrier indexes, immunoglobulin and inflammatory response indicators were compared between two groups of patients before and after treatment.Results: Before treatment, differences in serum levels of intestinal mucosal barrier indexes, immunoglobulin and inflammatory response indicators were not statistically significant between the two groups of patients. After treatment, serum intestinal mucosal barrier indexes Endotoxin, D-Lactate and DAO levels in observation group were lower than those in control group, immunoglobulin IgA, IgM and IgG levels were higher than those in control group, and inflammatory response indicators IL-1, IL-6, PCT and TNF-α levels were lower than those in control group patients. Conclusion:Perioperative r-hGH application in patients with intestinal obstruction can protect the intestinal mucosal barrier, also optimize the humoral immunity and suppress the systemic inflammatory response.

Improved Cardiac Contractility of Human Recombinant Growth Hormone on the Congestive Heart Failure of Pig

The enhanced cardiac contractility effect of human recombinant growth hormone (hr-GH) on the congestive heart failure (CHF) was studied on the pig. To build a pig model of congestive heart failure, a temporary artificial cardiac pacemaker was implanted in the pig’s body and paced at 220 beats to 240 beats per minute for 1 week. After the model of congestive heart failure was successfully set up, the frequency of the pacemaker was changed to 150 beats to 180 beats per minute to maintain the CHF model stable. Pigs were divided into three groups: The hr-GH group in which 0.5 mg/kg per day of hr-GH was administrated intramuscularly for 15 days, the injection control group in which an equal amount of physiological saline was injected intramuscularly, and a normal control group. The left ventricular diastolic end pressure was (10.60±2.41) mmHg in the hr-GH group, but (19.00±3.81) mmHg in the saline control group (P<0.01); Cardiac output was (1.86±0.13) L/min in the hr-GH group, but (1.56±0.18) L/min in the saline control group (P<0.05); Peripheral vascular resistance was (56.88±7.51) mmHg·(L/min) -1 in the hr-GH group, whereas (70.30±11.59) mmHg·(L/min) -1 in the saline control group (P<0.05); +dp/dt max was (2900±316.23) and (2280±286.36) in the hr-HG group and the saline control group respectively (P<0.05). The results show that hr-GH enhances myocardial contractility of CHF, and the CHF model built by a temporary artificial cardiac pacemaker at a high rate of stimulation is reasonable and applicable.

Growth-Promoting Effect of Recombinant Human Growth Hormone and Stanozolol in Girls with Turner Syndrome

Summary: Ten girls with Turner syndrome were treated with a combination therapy of recombinant human growth hormone (R hGH) and low dose stanozolol for a period of 8 to 36 months. The results showed that when compared with the growth rate before the treatment, the growth rates after treatment with R hGH and stanozolol showed a sustained increase, reaching 9.0±1.9 cm/year during the first year of treatment; the height age increase by 2.5±0.8 years while the bone age increase were 1.0±0.7 years; and the predicted final adult height at the end of the first year of the treatment increased to 149.4±6.1 cm compared to their original mean of 142.8±4.2 cm. We are led to conclude that therapy with R hGH in combination with stanozolol can increase the growth velocity and significantly increase the predicted adult height of children with Turner syndrome.

Effects of different doses of long-acting growth hormone in treating children with growth hormone deficiency

BACKGROUND With the improvement of economy and living standards,the attention paid to short stature in children has been increasingly highlighted.Numerous causes can lead to short stature in children,among which growth hormone deficiency(GHD)is a significant factor.AIM To investigate the long-term efficacy and safety of different doses of long-acting polyethylene glycol recombinant human growth hormone(PEG-rhGH)in the treatment of GHD in children.METHODS We selected 44 pediatric patients diagnosed with GHD who were treated at Wuhu First People's Hospital from 2014 to 2018.Total 23 patients were administered a high dose of long-acting PEG-rhGH at 0.2 mg/kg subcutaneously each week,forming the high-dose group.Meanwhile,21 patients were given a lower dose of long-acting PEG-rhGH at 0.14 mg/kg subcutaneously each week,establishing the low-dose Group.The total treatment period was 2 years,during which we monitored the patients’height,annual growth velocity(GV),height standard deviation score(HtSDS),chronological age(CA),bone age(BA),and serum levels of insulin-like growth factor-1(IGF-1)and insulin-like growth factor-binding protein-3(IGFBP-3)before treatment and at 6 mo,1 year,and 2 years after treatment initiation.We also monitored thyroid function,fasting plasma glucose,fasting insulin,and other side effects.Furthermore,we calculated the homeostatic model assessment for insulin resistance.RESULTS After 1 year of treatment,the GV,HtSDS,IGF-1,BA,and IGFBP-3 in both groups significantly improved compared to the pre-treatment levels(P<0.05).Moreover,when comparing GV,HtSDS,IGF-1,BA,and IGFBP-3 between the two groups,there were no statistically significant differences either before or after the treatment(P>0.05).During the treatment intervals of 0-1.0 years and 1.0-2.0 years,both patient groups experienced a slowdown in GV and a decline in HtSDS improvement(P<0.05).CONCLUSION The use of PEG-rhGH in treating GHD patients was confirmed to be effective,with similar outcomes observed in both the high-dose group and low-dose groups,and no significant differences in the main side effects.

戈舍瑞林联合rhGH对中枢性性早熟患儿生长速度、子宫与卵巢容积及骨代谢的影响

目的探讨戈舍瑞林联合重组人生长激素(rhGH)对中枢性性早熟患儿生长速度、子宫与卵巢容积及骨代谢的影响。方法选取遵化市人民医院于2020年5月至2022年4月收治的84例诊断为中枢性性早熟的女童作为研究对象,采用随机数字表法分为观察组(n=42)和对照组(n=42)。对照组采用皮下注射戈舍瑞林治疗,观察组在对照组基础上加用rhGH治疗。计算两组患儿治疗前后生长速度、测定骨龄及预测成年身高;B超下观察并计算两组患儿子宫和卵巢容积;采用电化学发光免疫分析法检测Ⅰ型原胶原氨基N端前肽(PINP)、Ⅰ型胶原羧基端肽交联(β-CTX)、骨钙素N端中分子片段(N-MID)水平;采用放射免疫法检测卵泡刺激素(FSH)、雌二醇(E_(2))和黄体生成素(LH)水平。结果治疗前两组患儿身高、预测成年身高、生长速度、骨龄、子宫和卵巢容积、PINP、β-CTX、N-MID、E_(2)、FSH和LH水平比较,差异无统计学意义(P>0.05)。治疗后两组患儿身高、预测成年身高及生长速度较治疗前增加,且观察组治疗后身高、预测成年身高、生长速度高于对照组(t=2.812、2.159、2.049,P<0.05);治疗后两组患儿子宫和卵巢容积较治疗前缩小,且观察组小于对照组(t=5.014、3.492,P<0.05);治疗后两组患儿PINP、N-MID、E_(2)、FSH和LH水平较治疗前下降,且观察组低于对照组(t=3.503、2.230、3.694、3.158、2.458,P<0.05)。观察组和对照组不良反应发生率比较,差异无统计学意义(P>0.05)。结论戈舍瑞林联合rhGH能够减缓中枢性性早熟患儿第二性征发育,调节骨代谢和性激素水平。

Effects of Recombinant Human Growth Hormone on Corneal Healing, Epithelial Nerve Regeneration and Tear Inflammatory Factors in Rabbits

Objective:The goal of this study is to investigate the effects of recombinant human growth hormone(rh GH)on corneal healing,epithelial nerve regeneration and tear inflammatory factor levels in rabbits.Methods:After corneal epithelial injury models were established,fifty adult clean New Zealand white rabbits were randomly divided into two groups,normal saline was administered to the control group,while recombinant human growth hormone was administered to the observation group.The healing rate of corneal epithelial injury,the regeneration ability of corneal epithelial nerve and the level of inflammatory factors in tears were observed and compared between the two groups of rabbits before and 24,48,72 and 96 h after modeling.Results:There were significant differences in corneal epithelial healing rate,time and interaction between the two groups(P<0.05).The experimental group exhibited a superior healing rate of corneal epithelium at 24,48,72,and 96 h compared to the control group(P<0.05).There were significant differences in central cornea sensitivity between the two groups,along with variations in time and interaction(P<0.05).There was no significant difference in the central corneal sensitivity between the two groups before modeling and at 24,72 and 96 h after modeling(P>0.05),whereas the experimental group exhibited a higher central corneal sensitivity compared to the control group at 48 h after modeling(P<0.05).There were significant differences in IL-1α,TNF-α,IL-17a and IL-21 between the two groups(P<0.05).There were significant differences in IL-17a and IL-21 between the two groups(P<0.05).The experimental group exhibited a significant decrease in IL-1αlevels compared to the control group between 24 and 72 h after modeling(P<0.05),the experimental group exhibited a substantial increase in IL-17a levels compared to the control group at 72 h after modeling(P<0.05),and the level of TNF-αin the experimental group was significantly lower than that of the control group between 24 and 96 h after modeling.Conclusion:Recombinant human growth hormone aids in expediting the healing process of the healing of rabbit corneal epithelial injury,facilitating the restoration of epithelial nerve,and mitigating the inflammatory response.

自制生长贴联合rhGH治疗儿童特发性矮身材的临床疗效观察

目的探讨自制生长贴联合重组人生长激素(rhGH)对儿童特发性矮身材(ISS)的临床疗效。方法选取2022年1月至12月在襄阳市中医医院就诊的90例ISS患儿,随机分为对照组1、对照组2和实验组,每组30例。对照组1予以rhGH治疗,对照组2予以自制生长贴治疗,实验组予以生长贴联合rhGH治疗,疗程均为12个月,比较三组治疗前、后身高和骨龄的变化情况。结果与治疗前相比,三组治疗后的身高值和骨龄均有明显增长(P<0.05);组间比较,三组的治疗效果相当(P>0.05)。治疗后实验组的生长速率明显快于两组对照组(P<0.05)。结论自制生长贴联合rhGH治疗儿童ISS能显著增高患儿身高,值得临床推广应用。

Changes in Serum Leptin Levels during r-hGH Treatment in Growth Hormone-Deficient Children

To observe the effect of growth hormone on serum leptin levels, serum leptin concentrations were measured by enzyme immunoassay in 12 prebutal children with growth hormone deficiency 1, 3 and 6 months before and after the treatment with recombinant human growth hormone (r hGH). For comparison, 34 normal prepubertal children were also investigated. Relationship between leptin levels and body mass index (BMI) was observed at the same time. Our results showed that serum leptin level in normal prepubertal children was 1.22±0.34 ng/ml; the pretreatment serun leptin levels in GHD children was 3.08±2.41 ng/ml, which was significantly different from those 1, 3 and 6 months after GH treatment (i.e. 1.64±1.37 ng/ml,1.57±1.40 ng/ml and 1.35±0.89 ng/ml respectively) (all P <0.001). Our results suggested that r hGH has a suppressive effect on leptin expression.

Optimizing growth in pediatric renal transplant recipients: An update

Growth retardation is a significant complication observed in pediatric renal transplant recipients,originating from a multifactorial etiology.Factors contributing to growth impairment encompass pre-transplant conditions such as primary kidney disease,malnutrition,quality of care,growth deficits at the time of transplantation,dialysis adequacy,and the use of recombinant human growth hormone.Additionally,elements related to the renal transplant itself,such as living donors,corticosteroid usage,and graft functioning,further compound the challenge.Although renal transplantation is the preferred renal replacement therapy,its impact on achieving final height and normal growth in children remains uncertain.The consequences of growth delay extend beyond the physi-ological realm,negatively influencing the quality of life and social conditions of pediatric renal transplant recipients,and ultimately affecting their educational and employment outcomes.Despite advancements in graft survival rates,growth retardation remains a formidable clinical concern among children undergoing renal transplantation.Major risk factors for delayed final adult height include young age at transplantation,pre-existing short stature,and the use of specific immunosuppressive drugs,particularly steroids.Effective management of growth retardation necessitates early intervention,commencing even before transplantation.Strategies involving the administration of recombinant growth hormone both pre-and post-transplant,along with protocols aimed at minimizing steroid usage,are important for achieving catch-up growth.This review provides a comprehensive outline of the multifaceted nature of growth retardation in pediatric renal transplant recipients,emphasizing the importance of early and targeted interventions to mitigate its impact on the long-term well-being of these children from birth to adolescence.INTRODUCTION Children with chronic kidney disease(CKD)endure frequent hospitalizations and ongoing treatment,which significantly affect their quality of life.One of the most noticeable effects of CKD in children is poor growth,with stunted height being a common sign of chronic malnutrition.Growth assessment involves regularly measuring weight and height/length and comparing these against z-score charts,along with other anthropometric indicators like head circumference and mid-upper arm circumference.Data from the North American Pediatric Renal Trials and Collaborative Studies(NAPRTCS)registry shows that over 35%of children enrolled had stunted growth at the time of admission,with growth impairment being more severe in younger children(58%in those aged under 1 year,compared to 22%in those aged over 12 years).Additionally,the same data revealed that growth impairment worsens as the severity of the disease increases.Although recent advances in science have enabled better outcomes for children with CKD,in resource-limited settings,numerous children are still deprived of achieving optimal growth owing to the disease and its related factors.Stunting is a key indicator of chronic growth impairment in children.A study by Wong et al[1]in the United States Renal Data System found that each SD decrease in height among children with stage V CKD is linked to a 14%increase in the risk of death[1].Similarly,research by Furth et al[2]using data from the NAPRTCS indicated that children with a height standard deviation score(SDS)of-2.5 face a relative hazard of death of 2.07.Stunting also correlates with increased hospitalizations.A study in the United States followed 1112 pediatric patients with end-stage renal disease from 1990 to 1995.It showed that children with severe or moderate growth failure had higher hospitalization rates compared to those with normal growth.Specifically,the relative risk for hospitalization was 1.14(95%CI:1.1-1.2)for those with moderate growth failure and 1.24(95%CI:1.2-1.3)for those with severe growth failure,even after adjusting for age,sex,race,cause,and duration of end-stage renal disease,and treatment type[2](dialysis or transplant).The growth of a child significantly affects his/her psychological and overall well-being as an adult.Short children are often embarrassed by peers,and it has been observed that height influences employment status,with unemployment being more prevalent among stunted individuals.Further,marital opportunities can be fewer among stunted individuals[3].Hence,all measures to achieve adequate growth should be attempted in children with CKD,regardless of whether they undergo transplantation.

维生素D钙咀嚼片联合rhGH治疗儿童生长激素缺乏症的临床效果

目的:探析维生素D钙咀嚼片联合重组人生长激素(rhGH)治疗儿童生长激素缺乏症(GHD)的临床效果。方法:采用目的抽样法纳入2022年1月—2023年12月石狮市医院收治的72例GHD患儿作为研究对象。采用随机数表法将纳入患者分为对照组和观察组,各36例。对照组给予rhGH治疗,观察组给予维生素D钙咀嚼片联合rhGH治疗,比较两组维生素D相关指标{25羟维生素D_(3)[25-(OH)D_(3)]、1,25-二羟维生素D_(3)[1,25-(OH)_(2)D_(3)]}、体格相关指标[身高标准差分值(HtSDS)、身高增长速度、骨龄]、骨代谢指标[碱性磷酸酶(BAP)、Ⅰ型骨胶原C终端端肽(ⅠCTP)、骨钙素]、甲状腺功能[游离三碘甲状腺原氨酸(FT_(3))、游离四碘甲状腺原氨酸(FT_(4))、促甲状腺激素(TSH)]、生长因子[胰岛素样生长因子-1(IGF-1)、胰岛素样生长因子结合蛋白-3(IGFBP-3)]、临床效果。结果:治疗前,两组维生素D相关指标、体格相关指标、骨代谢指标、甲状腺功能及生长因子水平比较,差异无统计学意义(P>0.05);治疗后,两组25-(OH)D_(3)、1,25-(OH)_(2)D_(3)、BAP、ⅠCTP、骨钙素、FT_(3)、FT_(4)、IGF-1、IGFBP-3水平、HtSDS、身高增长速度、骨龄高于治疗前,TSH水平低于治疗前,且观察组优于对照组,差异有统计学意义(P<0.05)。观察组临床总有效率为94.44%,高于对照组的77.78%,差异有统计学意义(P<0.05)。结论:维生素D钙咀嚼片联合rhGH治疗儿童GHD临床效果确切,与单用rhGH相比,可以更好改善患儿维生素D相关指标、体格相关指标、骨代谢指标、甲状腺功能及生长因子,同时也能有效提升治疗效果。

Effects of recombinant human growth hormone (r-hGH) on experimental osteoporotic fracture healing

Objective:: To observe the effect of recombinant human growth hormone (r-hGH) on osteoporotic fracture healing in rats, and to provide an effective therapy for osteoporotic fracture. Methods: Thirty-six female 8-month-old SD rats were randomized into two groups: therapy group and control group. After the experimental model of osteoporotic fracture was established, the therapy group was treated with r-hGH of 2.7 mg/kg body weigh/day (1 mg=3 IU) for 10 days continuously by daily subcutaneous injection; whereas the control group was treated with equivalent saline. Plasma insulin-like growth factor I concentration was detected and bone mineral density (BMD) as well as biomechanical strength of callus were measured at 2, 4, 8 weeks. Results: Plasma insulin-like growth factor I concentration in the therapy group was higher than that in the control group (P< 0.005 ) at 2nd week and began to decline at 4th week. At 8th week, there was no significant difference between the two groups. At 4th week, callus area and BMD in therapy group were higher than those in the control group, but at 8th week, they were lower and BMD had a significant difference between the two groups (P< 0.001 ). Biomechanical testing of callus showed that torsional strength of the therapy group was higher than that of the control group at 4th or 8th week, meanwhile maximum torsional angle had a significant difference between the two groups (P< 0.005 ).Conclusions: The results show that exogenous r-hGH can stimulate osteoporotic fracture healing in rats.

维生素D结合不同剂量rhGH治疗特发性矮小症的临床研究

目的:探讨维生素D结合不同剂量重组人生长激素(rhGH)对特发性矮小症(ISS)患儿的治疗效果及血清胰岛素样生长因子结合蛋白3(IGFBP-3)、皮质醇水平和骨龄的影响。方法:选取118例ISS患儿为研究对象,按治疗方法不同将患儿分为高剂量组(n=61)和低剂量组(n=57)。高剂量组给予维生素D+0.2 IU·kg^(-1)·d^(-1)rhGH治疗;低剂量组给予维生素D+0.15 IU·kg^(-1)·d^(-1)rhGH治疗,两组患儿疗程均为1年。比较两组患者治疗前后生长发育情况、血清骨代谢指标、IGFBP-3、皮质醇水平、骨龄指标及治疗期间不良反应。结果:治疗后,两组患儿身高、体重、血清骨钙素(OC)、骨碱性磷酸酶(BALP)、25羟基维生素D[25-(OH)D]、IGFBP-3水平、骨龄指数(BAI)、骨龄年龄差(BDA)均升高(P<0.05),且高剂量组高于低剂量组(P<0.05);身高标准差积分(Ht SDS)、血清皮质醇水平均降低(P<0.05),且高剂量组低于低剂量组(P<0.05)。治疗期间,两组患儿不良反应发生率比较,差异无统计学意义(P>0.05)。结论:维生素D结合高剂量rhGH对ISS患儿治疗效果更佳,且能改善血清IGFBP-3、皮质醇及骨龄水平,值得临床推广应用。

异功散加味联合rhGH对特发性矮小症患儿生长发育及IGF-1的影响

目的 探讨异功散加味联合重组人生长激素(recombinant human growth hormone,rhGH)对脾肾虚弱型特发性矮小症(idiopathic short stature,ISS)患儿生长发育及血清胰岛素样生长因子-1(insulin-like growth factor-1,IGF-1)水平的影响。方法 选取2020年6月至2021年6月于温州市中心医院就诊的脾肾虚弱型ISS患儿80例,根据随机数字表法将其分为对照组和治疗组,每组各40例。对照组患儿给予rhGH注射液治疗;治疗组患儿在对照组治疗的基础上联合异功散加味治疗。两组患儿连续治疗12个月。比较两组患儿的生长发育情况、脾肾虚弱证单项症状评分、临床疗效、血清IGF-1水平和不良反应发生率。结果 干预12个月后,两组患儿的身高、骨龄、血清IGF-1水平均显著高于本组治疗前,脾肾虚弱证单项症状评分均显著低于本组治疗前(P<0.05);治疗组患儿的身高、骨龄、血清IGF-1水平均显著高于对照组,脾肾虚弱证单项症状评分均显著低于对照组(P<0.05)。治疗组患儿的总有效率显著高于对照组(χ^(2)=4.132,P=0.042)。治疗组患儿的不良反应发生率显著低于对照组(χ^(2)=5.400,P=0.020)。结论 异功散加味联合rhGH治疗脾肾虚弱型ISS患儿的疗效较好,有利于促进患儿生长发育,改善中医证候评分,上调血清IGF-1水平,且安全性良好。

特发性矮小症患儿rhGH治疗前后血清促酰化蛋白水平变化及与疗效的相关性分析

目的探讨分析特发性矮小症患儿重组人生长激素(rhGH)治疗前后血清促酰化蛋白水平(ASP)变化及与疗效的相关性。方法选取2020年6月至2021年6月秦皇岛市妇幼保健院收治的124例特发性矮小症患儿作为观察组,予以rhGH治疗,并选取同期体检无异常的儿童80例作为对照组。收集研究对象入院时、治疗3个月后及治疗6个月后身高、体重和生长速率,并采用酶联免疫吸附法检测各时间点血清ASP水平、胰岛素样生长因子-1(IGF-1),分析治疗前后其水平变化及与rhGH治疗效果的关系。结果特发性矮小症患儿身高、生长速率、血清ASP、IGF-1水平均低于正常儿童(t值分别为5.901、34.128、15.076、11.790,P<0.05);治疗前、治疗3个月后、治疗6个月后患儿身高、血清ASP、IGF-1水平均依次增高,差异有统计学意义(F值分别为21.958、102.747、320.636,P<0.05);治疗6个月后特发性矮小症患儿身高增长和生长速率均高于治疗3个月(t值分别为26.320、4.019,P<0.05);Pearson相关性分析结果显示,治疗3个月后、治疗6个月后血清ASP水平与患儿身高、体重、生长速率均呈正相关关系(r值介于0.478~0.571之间,P<0.05);治疗6个月后,血清ASP与IGF-1呈正相关关系(r=0.413,P<0.05)。结论特发性矮小症患儿经rhGH治疗后血清ASP水平升高,其水平与患儿身高、体重、生长速率、IGF-1呈正相关关系,其水平变化与患儿生长发育密切相关,可为rhGH促生长治疗效果评估提供重要参考依据。

IGFALS基因多态性与特发性矮小症患儿rHGH治疗效果及血清IGF-1水平的关系

目的探究胰岛素样生长因子不稳定亚单位(IGFALS)基因多态性与特发性矮小症(ISS)患儿重组人生长激素(rHGH)治疗效果及血清胰岛素样生长因子-1(IGF-1)水平的关系。方法选择2021年1月至2022年8月大理白族自治州人民医院收治的120例ISS患儿作为ISS组,另选健康儿童120例作为对照组,提取两组外周血全基因组DNA,扩增IGFALS基因rs767089671位点基因片段并进行测序。采用rHGH治疗ISS患儿12个月,比较不同IGFALS基因分型患儿生长速率(GV)、年龄对应身高标准差积分(HtSDS)、血清IGF-1、胰岛素样生长因子结合蛋白3(IGFBP-3)水平变化,分析IGFALS基因多态性与rHGH治疗效果及血清IGF-1水平的关系。结果ISS组和对照组IGFALS基因rs767089671位点的基因分型分布符合Hardy-Weinberg平衡定律(P>0.05);ISS组IGFALS基因rs767089671(c.1310C>T)位点基因分型及C/T等位基因分布频率与对照组比较差异有统计学意义(P<0.05);治疗前不同基因分型患儿性别、年龄、体质量、身高、遗传靶身高、骨龄比较差异无统计学意义(P>0.05);治疗后不同基因分型患儿GV、HtSDS、血清IGFBP-3、IGF-1水平均升高,且CC型患儿GV、HtSDS、血清IGFBP-3、IGF-1水平变化更明显(P<0.05);Spearman相关性分析显示,ISS患儿治疗前血清IGF-1、IGFALS基因多态性与治疗前后ΔHtSDS呈正相关(r=0.932、0.576,P<0.05)。结论ISS患儿IGFALS基因rs767089671位点多态性与rHGH促生长效果有关,且GV增长不明显可能与CT和TT基因分型患儿血清IGF-1水平增加不足有关。

注射用rhGH联合注射用胸腺肽α1治疗老年重症肺炎患者的效果

目的:研究注射用重组人生长激素(rhGH)联合注射用胸腺肽α1治疗老年重症肺炎患者的效果。方法:回顾性分析2022年1—6月福建医科大学附属泉州市第一医院收治的100例老年重症肺炎患者的临床资料。根据不同治疗方式将其分为对照组(n=48)和观察组(n=52)。两组入院后均接受常规治疗,观察组给予注射用rhGH联合注射用胸腺肽α1治疗,对照组给予注射用rhGH治疗。比较两组治疗2周后临床效果,治疗前及治疗2周后免疫功能、炎症因子及不良反应。结果:观察组总有效率显著高于对照组,差异有统计学意义(P<0.05)。治疗2周后,两组CD3^(+)、CD4^(+)升高,CD8^(+)降低,观察组CD3^(+)、CD4^(+)高于对照组,CD8^(+)低于对照组,差异有统计学意义(P<0.05)。治疗2周后,观察组C反应蛋白(CRP)、降钙素原(PCT)水平均低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:注射用rhGH联合注射用胸腺肽α1治疗老年重症肺炎患者可改善临床症状,提高免疫功能,降低炎症因子水平,效果较好。